Prostate Cancer, PSA
Conditions
Keywords
Prostate Cancer, PSA, Glycomics Assay
Brief summary
The principal aim of this pilot study is to test whether the PSA Glycomics Assay on urine and serum samples can provide insights regarding the disease state of patients with elevated PSA concentrations, as well as to accurately identify if the patient has prostate cancer and, in the case of prostate cancer, to determine its level of aggressiveness.
Interventions
DIAGNOSTIC_TESTPSA Glycomics Assay
PSA Glycomics Assay will be performed on urine and blood samples
Sponsors
Amsterdam UMC, location VUmc
The Netherlands Cancer Institute
Radboud University Medical Center
Leiden University Medical Center
Prof.dr. H.P. Beerlage
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with elevated PSA (\>3 ng/mL) * Signed informed consent
Exclusion criteria
* Patients that have a cystitis (bladder infection) * Patients under chemotherapy * Patients using 5-alpha reductase inhibitors * History or presence of cancers, or non-prostate urological disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PSA Glycomics Assay | 1 year | The relative abundance of glycoforms of PSA in plasma and urine from the subjects will be measured. These will be related to the stage of PCa and compared to non-prostate cancer patients. |
Countries
Netherlands
Contacts
Primary ContactJ R Oddens, MD, PhD
Outcome results
None listed